Ophthalmology
Volume 115, Issue 12 , Pages 2146-2152.e1 , December 2008

Treatment of Ocular Mucous Membrane Pemphigoid with Immunosuppressive Drug Therapy

  • Jennifer E. Thorne, MD, PhD

      Affiliations

    • Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Epidemiology, Center for Clinical Trials, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
    • Corresponding Author InformationCorrespondence: Jennifer E. Thorne, MD, PhD, Wilmer Eye Institute, 550 North Broadway, Suite 700, Baltimore, MD 21205
    • ,
  • Fasika A. Woreta, MD, MPH

      Affiliations

    • Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Douglas A. Jabs, MD, MBA

      Affiliations

    • Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Epidemiology, Center for Clinical Trials, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Grant J. Anhalt, MD

      Affiliations

    • Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Received 5 March 2008 ,Revised 3 June 2008 ,Accepted 1 August 2008.

References 

  1. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–561
  2. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111:45–52
  3. Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002;109:111–118
  4. Foster CS, Sainz de la Maza M. Ocular cicatricial pemphigoid review. Curr Opin Allergy Clin Immunol. 2004;4:435–439
  5. Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res. 2004;23:579–592
  6. Hingorani M, Lightman S. Ocular cicatricial pemphigoid. Curr Opin Allergy Clin Immunol. 2006;6:373–378
  7. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–379
  8. Thorne JE, Anhalt GJ, Jabs DA, et al. Role of electron microscopy in the diagnosis of ocular mucous membrane pemphigoid. Ophthalmology. 2006;113:1651–1656
  9. Thorne JE, Anhalt GJ, Jabs DA. Ocular mucous membrane pemphigoid. Dermatol Ther. 2002;15:389–396
  10. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982;89:340–353
  11. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol. 2002;138:380–384
  12. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983;96:453–459
  13. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea. 1991;10:185–195
  14. McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology. 2004;111:796–801
  15. Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol. 2005;6:93–103
  16. Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111:303–310
  17. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol. 2005;140:509–516
  18. Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121:466–476
  19. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112:1472–1477
  20. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid: strategies and outcomes. Ophthalmology. 2008;115:253–261
  21. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477–484

 Manuscript no. 2008-290.

 Dr Jabs is now at the Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York.

 Supported by the National Eye Institute, Baltimore, Maryland (grant nos.: EY-13707 [JET] and EY-00405 [DAJ]); and the Mildred Weiner Ocular MMP Research Fund, Baltimore, Maryland (JET). Dr Thorne is the recipient of a Research to Prevent Blindness Harrington Special Scholars Award.

 Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

PII: S0161-6420(08)00740-9

doi: 10.1016/j.ophtha.2008.08.002

Ophthalmology
Volume 115, Issue 12 , Pages 2146-2152.e1 , December 2008

Article Tools

* Image Usage & Resolution